Clinical Trial Update: Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three regimens for intermediate-risk HPV-positive oropharyngeal squamous cell carcinoma: cisplatin with radiotherapy, durvalumab with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING